Ravi Ajay Shah

Ravi Ajay Shah

Auto-generated profile, based on publicly available information

Ravi Ajay Shah

Institute of Cardiovascular Science, University College London , Rayne Building, University Street, London WC1E 6BT

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2022 in Circulation
Verified
Journal Article
Closed access
PDF file
RSRavi A. Shah
Ravi A. Shah
BABabken Asatryan
Babken Asatryan
GDGhaith Sharaf Dabbagh
Ghaith Sharaf Dabbagh
NANay Aung
Nay Aung
MKMohammed Y. Khanji
Mohammed Y. Khanji
OIon behalf of the Genotype-First Approach Investigators
on behalf of the Genotype-First Approach Investigators
Background: There is a paucity of data regarding the phenotype of dilated cardiomyopathy (DCM) gene variants in the general population. We aimed to determine the frequency and penetrance of DCM-associated putative pathogenic gene variants in a general adult population, with a focus on the expression of clinical and subclinical phenotype, including structural, functional, and arrhythmic disease features. Methods: UK Biobank participants who had undergone whole exome sequencing, ECG, and cardiovascular magnetic resonance imaging were selected for study. Three variant-calling strategies (1 primary and 2 secondary) were used to identify participants with putative pathogenic variants in 44 DCM genes. The observed phenotype was graded DCM (clinical or cardiovascular magnetic resonance diagnosis); early DCM features, including arrhythmia or conduction disease, isolated ventricular dilation, and hypokinetic nondilated cardiomyopathy; or phenotype-negative. Results: Among 18 665 individuals included in the study, 1463 (7.8%) possessed ≥1 putative pathogenic variant in 44 DCM genes by the main variant calling strategy. A clinical diagnosis of DCM was present in 0.34% and early DCM features in 5.7% of individuals with putative pathogenic variants. ECG and cardiovascular magnetic resonance analysis revealed evidence of subclinical DCM in an additional 1.6% and early DCM features in an additional 15.9% of individuals with putative pathogenic variants. Arrhythmias or conduction disease (15.2%) were the most common early DCM features, followed by hypokinetic nondilated cardiomyopathy (4%). The combined clinical/subclinical penetrance was ≤30% with all 3 variant filtering strategies. Clinical DCM was slightly more prevalent among participants with putative pathogenic variants in definitive/strong evidence genes as compared with those with variants in moderate/limited evidence genes. Conclusions: In the UK Biobank, ≈1 of 6 of adults with putative pathogenic variants in DCM genes exhibited early DCM features potentially associated with DCM genotype, most commonly manifesting with arrhythmias in the absence of substantial ventricular dilation or dysfunction.

13 September 2023 in JACC: Heart Failure
Verified
Journal Article
Open access
BABabken Asatryan
Babken Asatryan
RSRavi A. Shah
Ravi A. Shah
GDGhaith Sharaf Dabbagh
Ghaith Sharaf Dabbagh
ALAndrew Landstrom
Andrew Landstrom
DDDawood Darbar
Dawood Darbar
CCC. Anwar A. Chahal
C. Anwar A. Chahal
Inherited cardiomyopathies present with broad variation of phenotype. Data are limited regarding genetic screening strategies and outcomes associated with predicted deleterious variants in cardiomyopathy-associated genes in the general population. The authors aimed to determine the risk of mortality and composite cardiomyopathy-related outcomes associated with predicted deleterious variants in cardiomyopathy-associated genes in the UK Biobank. Using whole exome sequencing data, variants in dilated, hypertrophic, and arrhythmogenic right ventricular cardiomyopathy-associated genes with at least moderate evidence of disease causality according to ClinGen Expert Panel curations were annotated using REVEL (≥0.65) and ANNOVAR (predicted loss-of-function) considering gene-disease mechanisms. Genotype-positive and genotype-negative groups were compared using time-to-event analyses for the primary (all-cause mortality) and secondary outcomes (diagnosis of cardiomyopathy; composite outcome of diagnosis of cardiomyopathy, heart failure, arrhythmia, stroke, and death). Among 200,619 participants (age at recruitment 56.46 ± 8.1 years), 5,292 (2.64%) were found to host ≥1 predicted deleterious variants in cardiomyopathy-associated genes (CMP-G+). After adjusting for age and sex, CMP-G+ individuals had higher risk for all-cause mortality (HR: 1.13 [95% CI: 1.01-1.25]; P = 0.027), increased risk for being diagnosed with cardiomyopathy later in life (HR: 5.75 [95% CI: 4.58-7.23]; P < 0.0001), and elevated risk for composite outcome (HR: 1.29 [95% CI: 1.20-1.39]; P < 0.0001) than CMP-G- individuals. The higher risk for being diagnosed with cardiomyopathy and composite outcomes in the genotype-positive subjects remained consistent across all cardiomyopathy subgroups. Adults with predicted deleterious variants in cardiomyopathy-associated genes exhibited a slightly higher risk of mortality and a significantly increased risk of developing cardiomyopathy, and cardiomyopathy-related composite outcomes, in comparison with genotype-negative controls.

18 October 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
BABabken Asatryan
Babken Asatryan
BMBrittney Murray
Brittney Murray
RTRafik Tadros
Rafik Tadros
MRMarina Rieder
Marina Rieder
RSRavi A. Shah
Ravi A. Shah
TIthe Genotype‐First Approach Investigators
the Genotype‐First Approach Investigators
Precision medicine, which among other aspects includes an individual's genomic data in diagnosis and management, has become the standard‐of‐care for Mendelian cardiovascular disease (CVD). However, early identification and management of asymptomatic patients with potentially lethal and manageable Mendelian CVD through screening, which is the promise of precision health, remains an unsolved challenge. The reduced costs of genomic sequencing have enabled the creation of biobanks containing in‐depth genetic and health information, which have facilitated the understanding of genetic variation, penetrance, and expressivity, moving us closer to the genotype‐first screening of asymptomatic individuals for Mendelian CVD. This approach could transform health care by diagnostic refinement and facilitating prevention or therapeutic interventions. Yet, potential benefits must be weighed against the potential risks, which include evolving variant pathogenicity assertion or identification of variants with low disease penetrance; costly, stressful, and inappropriate diagnostic evaluations; negative psychological impact; disqualification for employment or of competitive sports; and denial of insurance. Furthermore, the natural history of Mendelian CVD is often unpredictable, making identification of those who will benefit from preventive measures a priority. Currently, there is insufficient evidence that population‐based genetic screening for Mendelian CVD can reduce adverse outcomes at a reasonable cost to an extent that outweighs the harms of true‐positive and false‐positive results. Besides technical, clinical, and financial burdens, ethical and legal aspects pose unprecedented challenges. This review highlights key developments in the field of genotype‐first approaches to Mendelian CVD and summarizes challenges with potential solutions that can pave the way for implementing this approach for clinical care.

11 November 2021 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
AJAkhilesh Jha
Akhilesh Jha
FCFangyue Chen
Fangyue Chen
SMSam Mann
Sam Mann
RSRavi Shah
Ravi Shah
RARanda Abu-Youssef
Randa Abu-Youssef
JFJonathan Fuld
Jonathan Fuld
Background: Prone positioning has a beneficial role in coronavirus disease 2019 (COVID-19) patients receiving ventilation but lacks evidence in awake non-ventilated patients, with most studies being retrospective, lacking control populations and information on subjective tolerability.Methods: We conducted a prospective, single-centre study of prone positioning in awake non-ventilated patients with COVID-19 and non-COVID-19 pneumonia. The primary outcome was change in peripheral oxygenation in proneversussupine position. Secondary outcomes assessed effects on end-tidal CO2, respiratory rate, heart rate and subjective symptoms. We also recruited healthy volunteers to undergo proning during hypoxic challenge.Results: 238 hospitalised patients with pneumonia were screened; 55 were eligible with 25 COVID-19 patients and three non-COVID-19 patients agreeing to undergo proning – the latter insufficient for further analysis. 10 healthy control volunteers underwent hypoxic challenge. Patients with COVID-19 had a median age of 64 years (interquartile range 53–75). Proning led to an increase in oxygen saturation measured by pulse oximetry (SpO2) compared to supine position (difference +1.62%; p=0.003) and occurred within 10 min of proning. There were no effects on end-tidal CO2, respiratory rate or heart rate. There was an increase in subjective discomfort (p=0.003), with no difference in breathlessness. Among healthy controls undergoing hypoxic challenge, proning did not lead to a change in SpO2or subjective symptom scores.Conclusion: Identification of suitable patients with COVID-19 requiring oxygen supplementation from general ward environments for awake proning is challenging. Prone positioning leads to a small increase inSpO2within 10 min of proning though is associated with increased discomfort.

3 October 2018 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
RSRavi Ajay Shah
Ravi Ajay Shah
In children with DKA (patient), do conservative rates of rehydration (intervention) decrease the risk of cerebral oedema (outcome)?

23 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
RORafael R. Oexner
Rafael R. Oexner
HAHyunchan Ahn
Hyunchan Ahn
KTKonstantinos Theofilatos
Konstantinos Theofilatos
RSRavi A. Shah
Ravi A. Shah
RSRobin Schmitt
Robin Schmitt
ASAjay M Shah
Ajay M Shah
Background and Aims: Prediction and early detection of heart failure (HF) is crucial to mitigate its impact on quality of life, survival, and healthcare expenditure. In this study, we explored the predictive value of serum metabolomics (168 metabolites detected by proton nuclear magnetic resonance ( 1 H-NMR) spectroscopy) for incident HF. Methods: We leveraged data of 68,311 individuals and > 0.8 million person-years of follow-up from the UK Biobank (UKB) cohort to assess individual metabolite associations and to train models to predict HF risk in individuals not previously considered at risk. Specifically, we (I) fitted per-metabolite COX proportional hazards (COX-PH) models to assess individual metabolite associations and (II) trained and internally validated elastic net (EN) models to predict incident HF using the serum metabolome. We benchmarked discriminative capacities against a comprehensive, well-validated clinical risk score (Pooled Cohort Equations to Prevent HF, PCP-HF 1 ). Results: During median follow-up of ≈ 12.3 years, several metabolites showed independent association with incident HF (90/168 adjusting for age and sex, 48/168 adjusting for PCP-HF; false discovery rate (FDR)-controlled P < 0.01). Performance-optimized risk models effectively retained key predictors representing highly correlated clusters (≈ 80 % feature reduction). The addition of metabolomics to PCP-HF improved predictive performance (Harrel’s C: 0.768 vs. 0.755.; continuous net reclassification improvement (NRI) = 0.287; relative integrated discrimination improvement (IDI): 17.47 %). Simplified models including age, sex and metabolomics performed almost as well as PCP-HF (Harrel’s C: 0.745 vs. 0.755, continuous NRI: 0.097, relative IDI: 13.445 %). Risk and survival stratification was improved by the integration of metabolomics. Conclusions: The assessment of serum metabolomics improves incident HF risk prediction. Scores based simply on age, sex and metabolomics exhibit similar predictive power to clinically-based models, potentially offering a cost- and time-effective, standardizable, and scalable single-domain alternative to more complex clinical scores.